Skip to main content
. 2021 Apr 1;11:7335. doi: 10.1038/s41598-021-86818-7

Table 2.

Identification of significant pre- and early-pregnancy factors for later gestational diabetes mellitus before and after adjusting for confounding factors.

Characteristics Model 0 Model 1 Model 2
OR 95% CI p OR 95% CI p OR 95% CI p
Pre-pregnancy BMI (per + 3 kg/m2) 1.28 1.26–1.29 < 0.001 1.23 1.21–1.24 < 0.001 1.22 1.21–1.24 < 0.001
Pre-pregnancy intake of folic acid (yes vs. no) 0.76 0.71–0.81 < 0.001 0.74 0.69–0.79 < 0.001 0.73 0.69–0.79 < 0.001
Hypertension (+ vs. −) 1.48 1.19–1.85 0.001 1.28 1.00–1.58 0.046 1.26 0.99–1.57 0.062
Hemopathy (+ vs. −) 0.95 0.77–1.18 0.663 0.95 0.76–1.18 0.634 0.95 0.76–1.18 0.614
Epilepsy (+ vs. −) 0.81 0.47–1.39 0.445 0.85 0.49–1.46 0.551 0.86 0.5–1.48 0.577
Hemoglobin (per + 40 g/L) 1.02 0.98–1.06 0.372 1.01 0.98–1.06 0.474 1.01 0.98–1.06 0.467
White cell count (per + 1 * 109) 1.10 1.1–1.11 < 0.001 1.11 1.1–1.11 < 0.001 1.11 1.10–1.11 < 0.001
Platelet count (per + 50 * 109) 1.06 1.05–1.07 < 0.001 1.06 1.05–1.07 < 0.001 1.06 1.05–1.07 < 0.001
Alanine transaminase (per + 20 U/L) 1.06 1.04–1.08 < 0.001 1.05 1.03–1.06 < 0.001 1.05 1.03–1.06 < 0.001
Aspartate aminotransferase (per + 20 U/L) 1.04 1.01–1.07 0.004 1.03 1.00–1.06 0.057 1.03 1.00–1.06 0.058
Albumin (per + 5 g/L) 0.85 0.84–0.86 < 0.001 0.86 0.85–0.88 < 0.001 0.86 0.85–0.87 < 0.001
Direct bilirubin (per + 5 μmol/L) 0.93 0.93–0.95 < 0.001 0.93 0.92–0.95 < 0.001 0.94 0.92–0.95 < 0.001
Creatinine (per + 15 μmol/L) 0.96 0.95–0.97 < 0.001 0.95 0.94–0.96 < 0.001 0.95 0.84–0.96 < 0.001
Blood urea nitrogen (per + 10 mmol/L) 1.02 0.94–1.10 0.708 1.03 0.95–1.12 0.456 1.02 0.94–1.11 0.560

OR odds ratio, 95% CI 95% confidence interval, BMI body mass index. No confounders were adjusted in model 0; variables under adjustment in model 1 included age, alcohol drinking, cigarette smoking, education, and age at menarche; additional variables under adjustment in model 2 included maternal family histories of diabetes mellitus and hypertension, and the presence of hemopathy, epilepsy, hyperthyroidism, cardiovascular diseases, liver diseases, kidney diseases, and lung diseases on the basis of model 1.